Takeda Manufacturing Austria AG
PolandAll drugs from this manufacturer
-
The medicine is used to treat congenital or acquired antithrombin III deficiency. Acquired deficiency may occur as a result of various clinical disorders.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human antithrombin iii 50 IU/ml; 500 IU ATC: B01AB02
-
The medicine is used to treat congenital or acquired antithrombin III deficiency. Acquired deficiency may occur as a result of various clinical disorders.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human antithrombin iii 1000 j.m. ATC: B01AB02
-
It is a tissue adhesive used in plastic and reconstructive surgery, as well as in the treatment of burns. It is used, among other things, for bonding skin grafts or flaps and for adhering artificial skin to the wound site.
Dosage form: solution for preparation of tissue adhesive
Active substance Dosage human fibrinogen 1 mg/ml aprotinin 3000 KIU/ml calcium chloride dihydrate 40 mcmol/ml human thrombin 4 j.m./ml -
The medicinal product is used for the treatment and prevention of bleeding in individuals with hemophilia A or B who have factor VIII or IX inhibitors. It may also be used in individuals without hemophilia who have acquired inhibitors of factors VIII, IX, or XI, and to assist in the complete elimination of factor VIII inhibitors during long-term treatment.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human plasma protein 20-60 mg/ml ATC: B02BD03
-
The medicinal product is used for the treatment and prevention of bleeding in patients with haemophilia A or B who have a factor VIII or IX inhibitor. It may also be used in individuals without haemophilia but with acquired inhibitors of factors VIII, IX, and XI, and to assist in the complete elimination of factor VIII inhibitors during long-term treatment.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human plasma protein 20-60 mg/1 mL factor viii inhibitor bypassing activity 50 units/1 mL ATC: B02BD03
-
The medicinal product is used to replenish and maintain circulating blood volume in situations where it is too low.
Dosage form: solution for infusion
Active substance Dosage human albumin 200 g/l ATC: B05AA01
-
The medicinal product is used to replenish and maintain circulating blood volume in patients who have experienced blood or fluid loss in specific medical circumstances.
Dosage form: solution for infusion
Active substance Dosage human albumin 200 g/l ATC: B05AA01
-
The medicinal product is used to replenish and maintain circulating blood volume in patients who have experienced blood or fluid loss in specific medical cases.
Dosage form: solution for infusion
Active substance Dosage human albumin 50 g/l ATC: B05AA01
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It may also be used for the treatment of bleeding in patients with von Willebrand disease if other methods are ineffective or contraindicated.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml von willebrand factor human 75 j.m./ml ATC: B02BD02
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It is also used for the treatment of bleeding in patients with von Willebrand disease if other methods are ineffective or contraindicated.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 50 j.m./ml von willebrand factor human 38 j.m./ml ATC: B02BD02
-
The medicinal product is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency. It may also be used for the treatment of bleeding in patients with von Willebrand disease if other treatment methods are ineffective or contraindicated.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor viii 100 j.m./ml von willebrand factor human 75 j.m./ml ATC: B02BD02
-
The medicine is used for the treatment and prevention of bleeding in patients with congenital hemophilia B. It helps to supplement factor IX deficiency, which reduces the tendency to bleed into joints, muscles, and internal organs.
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor ix 1200 j.m. ATC: B02BD04
-
The medicine is used for the treatment and prevention of bleeding in patients with congenital hemophilia B. It helps to supplement factor IX deficiency, which reduces the tendency to bleed into joints, muscles, and internal organs.
Dosage form: solution for injection or infusion, powder and solvent for preparation of
Active substance Dosage human coagulation factor ix 600 j.m. ATC: B02BD04
-
The medicine is used for the treatment of bleeding, for the prevention of bleeding immediately before and after surgery, and in cases of congenital or acquired deficiency of blood clotting factors.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human coagulation factor ii 480 - 900 IU human coagulation factor vii 500 j.m. human coagulation factor ix 600 j.m. human coagulation factor x 600 j.m. c protein 400 j.m. ATC: B02BD01
-
The medicine is used for the treatment of bleeding, the prevention of bleeding immediately before and after surgery, and in cases of congenital or acquired deficiency of blood clotting factors.
Dosage form: solution for injection, powder and solvent for preparation of
Active substance Dosage human prothrombin complex 500 j.m. ATC: B02BD01
-
The medicine is used in adults with severe alpha1-proteinase inhibitor deficiency who have developed emphysema. It helps protect lung tissue and slows the progression of the disease, although it does not reverse existing damage.
Dosage form: powder and solvent for preparation of concentrate for infusion solution
Active substance Dosage human alpha1-proteinase inhibitor 500 mg ATC: B02AB02
-
The medicine is used in adults with diagnosed severe alpha1-proteinase inhibitor deficiency who have developed emphysema. It helps protect lung tissue and slows the progression of the disease.
Dosage form: powder and solvent for preparation of infusion solution
Active substance Dosage human alpha1-proteinase inhibitor 1000 mg ATC: B02AB02
-
It is a tissue adhesive used by surgeons as support in the healing process. It helps improve blood clotting, facilitates wound healing, serves as a sealing material for sutures in vascular and gastrointestinal surgery, and helps in bonding tissues, for example, when fixing skin grafts.
Dosage form: solution for preparation of tissue adhesive
Active substance Dosage aprotinin 3000 KIU fibrinolysin humanum 91 mg thrombin 4 500 j.m. calcium chloride dihydrate 40 mcmol ATC: V03A
-
It is a two-component tissue adhesive used by surgeons as a support when standard methods are insufficient. It helps improve blood clotting, serves as an adhesive to facilitate wound healing, acts as a sealant for sutures in vascular and gastrointestinal surgery, or for adhering tissues, e.g., when fixing skin grafts.
Dosage form: powder and solvent for preparation of tissue adhesive solution
Active substance Dosage aprotinin 3000 KIU calcium chloride dihydrate 40 mcmol human fibrinogen 91 mg human thrombin 500 j.m. ATC: V03A